On August 21, Bristol-Myers Squibb rose 3.02% in regular trading, trading at $67.45/share, with turnover of $158 million. The stock rebounded sharply after declining over 3% in the prior session.

On the news front, Bristol-Myers Squibb announced a collaboration with Chai Discovery on antibody research, leveraging Chai's AI molecular folding and design models to accelerate drug discovery and explore targets that are difficult to reach through traditional methods. The partnership marks another step in the company's expanding use of artificial intelligence in therapeutic development.

The broader pharmaceutical sector rallied in tandem, with Merck gaining 3.49%, Pfizer up 2.18%, Eli Lilly rising 1.92%, and Johnson & Johnson advancing 1.51%, reflecting strong sector-wide momentum. The rebound also carries a technical recovery component following the previous session's broad sector pullback.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)